Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA)

Gefitinib (IRESSA), an epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor, has antitumour activity in the advanced non-small-cell lung cancer (NSCLC) setting. However, in chemotherapy-naïve patients with advanced NSCLC, the addition of gefitinib to standard chemotherapy regimens...

Descripción completa

Detalles Bibliográficos
Autores principales: Kokubo, Y, Gemma, A, Noro, R, Seike, M, Kataoka, K, Matsuda, K, Okano, T, Minegishi, Y, Yoshimura, A, Shibuya, M, Kudoh, S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362053/
https://www.ncbi.nlm.nih.gov/pubmed/15870831
http://dx.doi.org/10.1038/sj.bjc.6602559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362053/
https://www.ncbi.nlm.nih.gov/pubmed/15870831
http://dx.doi.org/10.1038/sj.bjc.6602559

Ejemplares similares